GÜVEN BEKTEMÜR, Esra Şafak YILMAZ, Elif Hilal VURAL, Enver Kağan ATİKELER, Banu BAYAR, Hakkı GÜRSÖZ

General characteristics of top 100 selling drugs: Turkish pharmaceutical market between 2003 and 2016

There have been many developments that affected the Turkish pharmaceutical market following the Health Transformation Program (2003) and Social Security Reform (2006). The objective of this study was to investigate effects of the developments in Turkish drug market between 2003 and 2006 on the general properties of top selling drugs. Sales figures of all pharmaceuticals between 2003-2016 were obtained from IMS-Health Turkey database. The top 100 pharmaceuticals with the highest sales for each year were included in the study. Pharmaceuticals classified according to their general characteristics (locally manufactured/imported/locally manufactured and imported, brand name/generic, biotech or blood products, ATC groupings). There were 2.593 brands of pharmaceuticals in 2003 and 4.461 in 2016. During the 14 years, total sales of pharmaceutical came up to 21.052.440.931 TRY from 5.487.899.850 TRY. Total sales of the top 100 pharmaceuticals in 2003 approximately was 2.1 billion TRY, and exceeded 6.9 billion TRY in 2016. In this top selling group, dominance of imported and brand name drugs has increased over the years. The total value of biotechnological pharmaceuticals in the top 100 pharmaceutical group increased from 100 million TRY in 2003 to 2.5 billion TRY in 2016. Biotechnological pharmaceuticals are all brand name drugs and imported. Pharmaceuticals in this group have been dominated by antibiotics between 2003-2011, and by oncology drugs for the following years. The result of our study demonstrated the importance of creating new molecules for the long-term, and producing pharmaceuticals with higher value added and more advanced technology in Turkey.

PDF

___

Reh, G., 2016 Global Life Sciences Outlook–Moving forward with cautious optimism. Report by the Deloitte Touche Tohmatsu Limited [https://www2 deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-HealthCare/gx-lshc-2016-life-sciences-outlook.pdf], date of access : 08.08.2018

Rickwood S, Kleinrock M, Núñez-Gaviria M. Report by the IMS Institute for Healthcare Informatics, The Global Use of Medicines: Outlook Through 2017. [http://www.quotidianosanita.it/allegati/allegato1501906.pdf], Date of access: 08.08.2018

T.C. Sağlık Bakanlığı, Kamu Müdahalelerinin 2008-2013 Dönemindeki Değer Bazında İlk 100 İlaç Üzerine Etkilerinin Analizi, Sağlık Teknolojisi Değerlendirme Raporu-I. Türkiye İlaç ve Tıbbi Cihaz Kurumu, Ağustos, Ankara, 2014. [https://titck.gov.tr/Dosyalar/Ilac/SaglikTeknolojileriDegerlendirme/ STDRaporu1.pdf], date of access: 08.08.2018

T.C. Sağlık Bakanlığı, 2014 Yılında Değer Bazında En Yüksek Satış Tutarına Sahip İlk 100 İlacın Değerlendirilmesi Ve 2012-2013 Yılları İle Karşılaştırılması, Sağlık Teknolojisi Değerlendirme Raporu-II. Yayın No:1038, Ankara, Ağustos 2016. [https://titck.gov.tr/Dosyalar/Ilac/ SaglikTeknolojileriDegerlendirme/STDRaporu2.pdf], date of access: 15.08.2018

T.C. Sağlık Bakanlığı, Türkiye İlaç Pazarındaki Değer Bazında Yüksek Satışa Sahip İlaçların Farmakoekonomik Açıdan Değerlendirilmesi: 2006-2015 Dönemi, Sağlık Teknolojisi Değerlendirme Raporu-IV, Yayın No:1058, Ankara, Aralık 2016. [https://titck.gov.tr/Dosyalar/Ilac/ SaglikTeknolojileriDegerlendirme/STDRaporu4.pdf], date of access: 15.08.2018

T.C. Sağlık Bakanlığı, Türkiye İlaç Pazarı Gözlem Raporu -1, Satış Hacmi ve Satış Değeri Açısından İlk 20 İlacın Pazardaki Durumu, Türkiye İlaç ve Tıbbi Cihaz Kurumu, 2014, Ankara. [https://www.titck.gov.tr/PortalAdmin/ Uploads/UnitPageAttachment/XswrEocV.pdf], date of access: 15.08.2018

T.C Kalkınma Bakanlığı, 10. Kalkınma Planı, Ankara, 2013 [http://www. resmigazete.gov.tr/eskiler/2013/07/20130706M1-1-1.doc], date of access: 15.08.2018

Deloitte, Life Sciences and Health Care Industry Group Analysis of Industry Report: Group Biotechnology, IBISWorld, USA, 2015. [https://www2. deloitte.com/content/dam/Deloitte/es/Documents/sanidad/Deloitte_ES_ Sanidad_Global-Life-Sciences-Outlook-2014.pdf] erişim tarihi: 15.08.2018

Vural EH. Overview of Bioeconomics in Turkey and in the World. Sağlık ve İnsan. 2013;17:16-7.

PhRMA, Pharmaceutical Research and Manufacturers of America, 2014 Biopharmaceutical Research Industry Profile, Washington, DC, 2015. [http:// www.phrma.org/sites/default/files/pdf/2014_PhRMA_PROFILE.pdf], date of access: 15.08.2018

Sheppard, A. Generic Medicines: Essential contributors to the long-term health of society. Sector Sustainability Challenges In Europe- IMS Health, UK, 2014. [https://www.hup.hr/EasyEdit/UserFiles/Granske_udruge/HUPUPL/IMS.pdf], date of access: 15.08.2018

Dylst P, Simoens S. Does the market share of generic medicines influence the price level? A European analysis. Pharmacoeconomics. 2011;29:87582..